Summary of Genscript Biotech Q4 2026 Earnings Call

1Key Financial Results and Metrics

Revenue: USD 404.2 million, up 27.3% year-over-year.

Adjusted Net Profit: USD 62.5 million, a 200% increase year-over-year.

Gross Profit: USD 226.7 million, up 48% year-over-year.

Life Science Group Revenue: USD 319 million, up 28.8% year-over-year.

Adjusted Operating Margin: 29.5%, marking a significant improvement.

Bestzyme Revenue: USD 30.4 million, up 7.4% year-over-year.

Operating Loss for ProGel: Narrowed to USD 6.5 million from USD 16.8 million in the previous year.

2Strategic Updates and Business Highlights

Genscript is leveraging AI to enhance operational efficiency, with 60% of labs equipped with AI-driven automation.

The company is focusing on AI-driven demand, particularly in the Life Science Group, which is seeing a shift from transactional to long-term partnerships with clients.

Genscript's integrated platforms are positioned to capture growth in AI-driven drug discovery, with significant investments in automation and digital operations.

The company is expanding its customer base, particularly among AI-focused biotech firms, which are driving higher order values and recurring revenue models.

Bestzyme is integrating AI into R&D, leading to improved efficiency and cost reductions.

3Forward Guidance and Outlook

Life Science Group: Revenue growth guidance raised to 25% to 30%, with an adjusted gross margin above 55% and operating margin above 25%.

ProGel: Expected to achieve positive EBITDA by 2027, with revenue growth projected at 25% to 30%.

Overall: Genscript anticipates continued strong demand in AI-driven applications and aims to maintain high-quality growth and shareholder value.

4Bad News, Challenges, or Points of Concern

While the company is experiencing strong growth, there are challenges related to the competitive landscape, particularly with companies like Tab in the gene services market.

The need for rapid validation of AI-generated candidates poses operational bottlenecks, which Genscript is addressing through infrastructure investments.

The market remains competitive, and Genscript must continue to differentiate itself through quality and speed of service.

5Notable Q&A Insights

Management highlighted three key drivers for growth: increased AI-related demand, a compounding and higher-quality customer base, and operational leverage from investments in automation.

The competitive landscape was discussed, with Genscript emphasizing its value proposition in speed and data quality compared to competitors.

The company is confident in its ability to scale operations and meet increasing demand, particularly in the AIDD space, which is expected to continue growing.

Management addressed capital allocation strategies, indicating a disciplined approach to investments while maintaining a strong cash position of approximately USD 830 million. Overall, Genscript's strong performance in Q4 2026 reflects its strategic focus on AI-driven growth, operational efficiency, and a diversified customer base, despite facing competitive pressures and operational challenges.